PRIMARY OBJECTIVES:~I. To determine the objective response rate to cilengitide in younger patients with recurrent or progressive high-grade glioma that is refractory to standard therapy.~SECONDARY OBJECTIVES:~I. To estimate the distribution of time to progression, time to treatment failure, and time to death in these patients.~II. To estimate the rate of toxicity, especially symptomatic intratumoral hemorrhage, in these patients.~III. To evaluate the pharmacokinetics of cilengitide in plasma using a limited sampling strategy.~IV. To evaluate the pharmacogenetic polymorphisms in drug transporters (eg, breast cancer resistance protein [BCRP], P-glycoprotein [P-gp]) and relate to cilengitide disposition.~OUTLINE:~Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up every 3 months for 2 years and then periodically for 3 years.
This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.